Antimicrobial Chemotherapy Conference

4 & 5 February 2025

This open-access, virtual conference is jointly organised by BSAC and GARDP.

For ACC2025, the collaborating organisations are CEPID ARIES and Fiocruz.

GARDP
Global Antibiotic Research & Development Partnership

BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY

CEPID ARIES
Antimicrobial Resistance Institute of São Paulo

FIOCRUZ

More information about ACC2025 as well as previous and future ACC conferences can be found here: www.acc-conference.com

Learn more about the conference organisers and collaborators:

GARDP: www.gardp.org

BSAC: www.bsac.org.uk

CEPID ARIES: site.unifesp.br/cepidaries

Fiocruz: portal.fiocruz.br

Programme - 4th February

All times are indicated in GMT

1300

Introductory remarks

Dr Alison Luckey, Associate Director Medical Sciences, GARDP

Session one: Keynote presentation

Chair: Dr Alison Luckey, Associate Director Medical Sciences, GARDP

1305

Global Challenges and Goals for AMR – Reflections from the UNGA High Level Meeting

Professor Ana Gales, Federal University of São Paulo, Brazil

1325

Q&A

1335

BREAK

Session two: Drug discovery: new targets and new chemistry

Chair: Dr Alan Hennessy, Discovery and Exploratory Research Team Leader, GARDP

1345

Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria

Dr Douglas Huseby, Department of Medical Biochemistry and Microbiology, Uppsala University

1400

The Ersilia Model Hub: Open Source AI for Antimicrobial Drug Discovery

Dr Miquel Duran-Frigola, Lead Scientist and Co-Founder, Ersilia Open Source Initiative

1415

Immunotherapy focused on infectious diseases

Pamela Brown, Head of Chemistry, Centauri Therapeutics Ltd

1430

Q&A

1440

BREAK

Session three: Preclinical antimicrobial development

Chair: Dr François Franceschi, GARDP

1450

FabI inhibitor for Neisseria gonorrhoeae (Debio1453)

Dr David Cameron, Molecular Microbiologist, Debiopharm

1510

EBL-1463, a non-beta-lactam PBP inhibitor impervious to beta-lactamase hydrolysis for the treatment of CRE infections

Dr Francois Moreau, Chief Scientific Officer, Tamrisa Innovation

1520

An Immune Approach for the Treatment of Sepsis

Dr Jessica Field, Cellics Therapeutics

1530

Q&A

1545

BREAK

Session four: Panel discussion - The antifungal development pipeline

Chair: Dr Susana Frasés Carvajal, Federal University of Rio de Janeiro

1555

Panel discussion

Panellist to be confirmed
Dr Maurizio Del Poeta, Stony Brook University, USA
Dr Leah Cowen, University of Toronto, Canada

1650

Q&A

1700

Closing remarks

Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer

Programme - 5th February

All times are indicated in GMT

1300

Introductory remarks

Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer

Session five: Clinical development and use of new agents

Chair: Dr Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary

1305

Presentation title to be confirmed

Halley Rogers, Director, Clinical Research, Clinical Development and Operations, Pfizer, Inc

1320

The challenges and opportunities of the development pathway for Phage therapy

Gregory Merril, Board Director, BiomX

1335

The challenges and opportunities in the preclinical development of cefepime-enmetazobactam

Dr Maneesh Paul, CEO, Microvioma

1350

Q&A

1400

BREAK

Session six: Oral poster resentations

Chair: Dr Tom Ashfield, Health Strategist & BSAC Council

1410

Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria

Dr Sohinee Sarkar, Murdoch Children's Research Institute, Australia

1415

Utilising actinobacteria diversity in the Great Salt Plains to look for novel TB therapeutics

Dr Amanda Jones, Northumbria University, Newcastle upon Tyne

1420

Building an on-panel enzyme detection system to reveal and resolve clinically problematic beta-lactamases in Gram negative bacteria

Dr Nicole Jackson, BioAmp Diagnostics

Session six continued ...

1425

Functional high-throughput screening identifies microRNAs regulating infection by Staphylococcus aureus

Dr Caio Haddad Franco, AccelBio Collaborative Laboratory, University of Coimbra

1430

Computational study to identify novel Metallo-β-lactamases inhibitors using virtual screening, molecular docking, dynamic simulations, and ADMET prediction

Fatima Mourabiti, University of Casablanca

1435

Q&A

1445

BREAK

Session seven: Control of infectious diseases with biotherapeutics and beyond

Chair: Dr Fausto Almeida, University of Sao Paulo

1455

The role of vaccines to tackle AMR

Professor Angela Brueggemann, University of Oxford

1510

Therapeutic antibodies and infectious diseases

Dr Liise-anne Pirofski, Physician-scientist & Chief, Division of infectious diseases & Dr Jacques and Selma Mitrani Chair, Biomedical Research, Albert Einstein College of Medicine & Montefiore Medical Center

1525

Jumbo Bacteriophages for IPC

Dr Gregorio Iraola, Co-founder & CEO, Kinzbio

1540

Q&A

1550

BREAK

Session eight: Panel discussion - Acceleration of development/access of POCTs for STI management

Chair: Dr Teri Roberts, Public Health Senior Manager, GARDP

1600

Panel discussion

Dr Yukari Manabe, Professor of Medicine, Johns Hopkins School of Medicine, Director, Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases

Dr Chido Dziva Chikwari, Assistant Professor, London School of Hygiene and Tropical Medicine (UK) & The Biomedical Research and Training Institute (Zimbabwe)

Dr Cecilia Ferreyra, Director of the AMR Programme, FIND

1655

Q&A

1705

Closing remarks

Dr Alison Luckey, Associate Director Medical Sciences, GARDP

Speakers

Dr Mike Allen

Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary

Mike has over 35 years of UK and Global pharmaceutical industry experience within the field of antibiotics, antimicrobial resistance and infectious disease. Mike started his career as a clinical pharmacologist working with the Pain & Opiate Research Group at the Nuffield Department of Anaesthetics in Oxford from 1979 to 1986.

Following appointments in Lederle Laboratories (later became Wyeth Pharmaceuticals), Novartis Pharmaceuticals and Cubist, Mike currently works as the Regional Medical Advisor (Antibiotics) and MSD Ltd UK, with medical responsibilities for MSD's broad portfolio of licensed antibiotics and pipeline molecules. Over his career in the pharmaceutical industry, he has worked collaboratively with the medical, commercial, policy and development teams at National, European and Global levels, including the coordination of a highly successful international antibiotic registry and multiple clinical and in vitro antibiotic studies.

Mike was elected to serve a 3-year term as General Secretary of BSAC in 2022 and has been an Ordinary Member of BSAC Council since 2018, having previously served as an Ordinary Member of Council from 2012-2015. He is a core member of the BSAC Resistance Surveillance Project Legacy Working Group, having served on the Steering Committee since the inception of the project in 1999, both as an industry representative and core member. Mike has been a member of the Antibiotic Research UK (ANTRUK) Scientific Committee since 2018.

Mike has co-authored over 40 publications with lead researchers in the UK and internationally, looking particularly at antibiotic resistance surveillance and the association between antibiotic use and infections caused by clinically significant pathogens including; Clostridium difficile, glycopeptide-resistant enterococci, MRSA, Pseudomonas aeruginosa and ESBL-producing Enterobacteriales

Dr Tom Ashfield

Health Strategist & BSAC Council

Tom Ashfield is a GP with experience as a pharmacist, hospital doctor and ENT surgical trainee. He has worked in all core acute specialties and has experience spanning from rural GP to specialist tertiary services. Since 2019 he has been a Senior Medical Advisor for AMS/AMR with Pfizer and maintains a part-time GP service via an online telemedicine platform. He is committed to stewardship in all aspects of his work and his wealth of experience provides great insight into the challenges and opportunities presenting to the modern healthcare system. In 2022, he and the diverse cross-industry and third sector members of the Infection Management Coalition released their White Paper on holistic infection management (www.theimc.org). Prior to this, Tom was closely involved with the preparation and clinical aspects of Pfizer's contribution to the world's first antimicrobial subscription model. His current work encompasses policy, media, patient engagement, digital and clinical research.

Pamela Brown

Head of Chemistry, Centauri Therapeutics Ltd

Pam has over 40 years experience in anti-infective drug discovery and medicinal chemistry, from Pharma (GSK and legacy companies) to Biotech (Cantab Anti-infectives, Spero Therapeutics) encompassing a wide variety of bacterial targets in hit-to-lead through lead optimisation to candidate selection. At Cantab this led to the discovery of SPR-206 which has recently completed Phase 1 trials. Pam joined Centauri Therapeutics in 2022 and has since been enjoying the challenges of working in the immunology space as a new approach to tackling antibiotic-resistant infections.

Professor Angela Brueggemann

University of Oxford

Angela Brueggemann has worked at the University of Oxford since 2000 and joined her current department in 2019. She established the Infectious Disease Epidemiology Unit (IDEU) in 2022. The IDEU is currently comprised of eight PIs and their research groups, who investigate a wide range of diseases caused by bacteria, viruses and parasites.

The Brueggemann research group analyses thousands of bacterial genomes to better understand diseases like meningitis and pneumonia, and the impact of vaccination and antimicrobial resistance. Current research projects include the Invasive Respiratory Infection Surveillance (IRIS) Consortium, a large international consortium of microbiology reference laboratories investigating the impact of the pandemic on the epidemiology of bacterial invasive disease, and other projects that are investigating bacteriocin peptides that might have potential as novel antimicrobials. A central component of their research includes making genomic data and analysis tools freely accessible to the international community through PubMLST.

Dr Chido Dziva Chikwari

Assistant Professor, London School of Hygiene and Tropical Medicine (UK) & The Biomedical Research and Training Institute (Zimbabwe)

Chido is an epidemiologist with experience developing, coordinating, and evaluating implementation research studies with particular focus on projects evaluating the provision of sexual and reproductive health services for adolescents and young people in facility and community-based settings. She was the principal investigator for the STICH trial; an evaluation of an STI screening intervention for youth and the Zimbabwe principal investigator for the GIFT study which is an evaluation of a new STI screening device. Her work has also involved validation of oral HIV tests for children and evaluating the use of assisted HIV testing for children by their caregivers. She is based in Zimbabwe and holds a joint appointment with the London School of Hygiene and Tropical Medicine (UK) and The Health Research Unit Zimbabwe at the Biomedical Research and Training Institute (Zimbabwe).

Dr David Cameron

Molecular Microbiologist, Debiopharm

David Cameron is a molecular microbiologist focused on developing new strategies to combat antimicrobial resistance. His early work was centred on defining genetic mechanisms of antibiotic resistance/tolerance and included research stints with Anton Peleg at Monash University in Melbourne, and Kim Lewis at Northeastern University in Boston. He arrived in Switzerland in 2018 where he worked closely with Yok-Ai Que to assess phage therapy for the treatment of staphylococcal infections in translational animal models. Currently, he is a senior scientist at Debiopharm International S.A. and functions as the lead microbiologist on each of the company's anti-infective programs.

Dr Maurizio Del Poeta

Stony Brook University, USA

Dr. Maurizio Del Poeta, MD, is a physician-scientist and a SUNY Distinguished Professor at Stony Brook University, Stony Brook, NY (USA) and the Chief Scientific Officer of MicroRid Technologies Inc., Dix Hills, NY (USA). The laboratory of Dr. Del Poeta studies fungal pathogenesis, vaccine development, and the discovery of new antifungal compounds for a more effective treatment of various fungal infectious diseases, particularly those infections caused by fungi resistant to clinically available drugs

Professor David Denning

Professor of Infectious Diseases and Global Health, The University of Manchester

David Denning is Professor of Infectious Diseases and Global Health at The University of Manchester having practiced as an infectious diseases clinician, with a special interest in fungal disease, for 40 years. He founded and then served as Chief Executive of Global Action For Fungal Infections (GAFFI) (2013-2023). GAFFI (www.GAFFI.org) advocates for universal access to fungal diagnostics and antifungal therapies. David managed the UK's National Aspergillosis Centre, Manchester from 2009-2020. He has published extensively (>750 academic papers) and has a citation H-index of 135. He has been the managing editor of the Aspergillus Website since 1998 (www.Aspergillus.org.uk). He leads LIFE (Leading International Fungal Education (http://fungaleducation.org/), which is focused on improving patient outcomes through online education. He has contributed to multiple guidelines for the diagnosis and treatment of serious fungal diseases.

Dr Miquel Duran-Frigola

Lead Scientist and Co-Founder, Ersilia Open Source Initiative

Miquel Duran-Frigola's research interests lay at the intersection between drug discovery and large-scale biological data analysis. During his PhD studies and early career, Miquel developed several in silico methods for pharmacology, producing scientific publications in a broad range of topics, from theoretical chemistry to cell-based data analysis. Along this process, he has worked at IRB Barcelona, the Massachusetts Institute of Technology (MIT), Tel Aviv University, ISGlobal-CISM (Mozambique), CIDRZ (Zambia), H3D (South Africa) and CeMM (Austria). At IRB Barcelona, Miquel led the development of the Chemical Checker, a data-driven drug discovery tool that collects and harmonises a massive amount of bioactivity data, making it ready for machine learning tasks.

Currently, Miquel is Lead Scientist at the Ersilia Open Source Initiative, a UK charity and Spanish Foundation aimed at implementing AI/ML tools in resource-limited countries, where he serves as Scientist and Trustee. Ersilia's main asset is the Ersilia Model Hub, an ever-growing repository of more than one hundred ready-to-use AI/ML models for antimicrobial drug discovery and global health. With Ersilia, Miquel hopes to apply his data science skills in underfunded settings such as research institutes in Low and Middle Income Countries. Beyond science, Miquel has a Master's degree in Creative Writing and studies Humanities, and has published a novel and several short stories in Catalan and Spanish.

Dr Jessica Field

Cellics Therapeutics

Jessica received her PhD in Biomedical Science at Victoria University of Wellington and has 11 years of experience in drug development. She specializes in advancing drug candidates from early-stage research through IND-filing and first in human clinical trials. Her work spans multiple therapeutic modalities across infectious and autoimmune diseases and oncology. In her current role at Cellics Therapeutics, Jessica leads nonclinical development focusing on pioneering cellular nanoparticles for infectious disease treatments. These cellular nanoparticles are both AMR and pathogen-agnostic, making them an innovative and promising new class of therapeutics. Jessica has authored or co-authored 26 articles and is a co-inventor on several patents.

Dr François Franceschi

Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader, GARDP

François Franceschi is Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader at the Global Antibiotic Research & Development Partnership (GARDP).

François has over 25 years of experience in antimicrobial research and development. He previously served as Program Officer for Therapeutics Development (antibacterial and antifungal) at the National Institute of Allergy and Infectious Diseases (NIAID) in Maryland, US. Here, he also served as NIAID's liaison to CARB-X and as a member of its Scientific and Milestone Review Boards. François has held various director positions within antimicrobial R&D such as at Rib-X Pharmaceuticals (now Melinta Therapeutics). François was previously a principal investigator at the Max Planck Institute for Molecular Genetics (MPI) in Berlin, Germany, where his research focused on the structure and function of ribosomes, especially in complex with antibiotics. His group was a pivotal part of an international consortium headed by Ada Yonath, who won the Nobel Prize in Chemistry in 2009.

François earned his PhD in Chemistry at the Freie Universität Berlin, Germany after being awarded his Bachelor's degree in Biology at Universidad Simon Bolívar, Venezuela.

Dr Cecilia Ferreyra

Director of the AMR Programme, FIND

Dr Cecilia Ferreyra is a Medical Doctor specialized in Infectious Diseases. Before joining FIND, Cecilia worked with Médecins Sans Frontières during 15 years in several countries such as Kenya, China, Somalia, DRC, South Sudan and Uganda, implementing HIV/TB activities in conflict affected populations. She also worked as HIV/TB Advisor and Leader of the International MSF AMR Task Force.

She joined FIND in 2018 and is currently the Director of the AMR Programme where she oversees all AMR projects addressing gaps in the availability and use of diagnostic tests to improve patient management and guide appropriate use of anti-microbials

Dr Alan Hennessy

Discovery and Exploratory Research Team Leader, GARDP

Alan Hennessy joined GARDP as Discovery and Exploratory Research Team Leader in June 2023. Prior to joining GARDP, Alan was most recently head of lead generation and group leader at Syngenta, Jealott's Hill, UK. He also held multiple roles at Syngenta in people and project leadership from 2011 and several of his projects have now successfully transitioned to the development phase.

He has also spent almost ten years working in anti-bacterial research for GSK, leading diverse medicinal chemistry teams. A highlight was the invention of key phase III antibacterial clinical candidate Gepotidacin (approval expected 2024).

He is an author on 25 papers and inventor on 54 published patents (including the key Gepotidacin patent). He has a PhD in Palladium catalysis from University College Dublin from where he also obtained his primary chemistry degree. Alan brings experience of modern medicinal chemistry research strategies from target selection and hit finding through to later stage lead optimization.

Dr Douglas Huseby

Department of Medical Biochemistry and Microbiology, Uppsala University

Douglas Huseby is a researcher and program manager for ENABLE-2 at the University of Uppsala in Uppsala, Sweden. His research career has focused on various topics in bacterial genetics, including evolution and mechanisms of antibiotic resistance and novel antibiotic development. He has worked since 2014 in the EU's Innovative Medicines Initiative New Drugs 4 Bad Bugs ENABLE program, and the Swedish follow-on, ENABLE-2. These programs have worked to connect early-stage antibiotic development programs with experimental resources in academia, and expertise from pharmaceutical companies and academia to develop their projects. In these programs, he has worked on many antibiotic discovery and development projects, helping to identify the mechanism of action and resistance mechanisms to novel antimicrobial compounds.

Dr Gregorio Iraola

Co-founder & CEO, Kinzbio

Dr Gregorio Iraola holds a biology degree from the Universidad de la República (Uruguay) and completed his master's in the field of bioinformatics at the Institut Pasteur Montevideo (Uruguay) before obtaining his Ph.D. focused on computational microbiology at the same institution. There, he then worked as an associate researcher to the Bioinformatics Unit before creating and becoming the Head of the Microbial Genomics Laboratory. He was also appointed as International Fellow at the Wellcome Sanger Institute (UK) and Adjunct International Professor at the Universidad Mayor (Chile). His research focused on understanding and combating bacterial infections and AMR from a one-health perspective, integrating the human microbiome to its surroundings. He has published over 50 original articles in peer-reviewed journals, spoken in several international conferences and workshops. He is part of the International Human Microbiome Coordination and Support Action and the MetaSUB International Consortium. Currently, he is cofonder and CEO of Kinzbio, a biotech startup developing preventives and therapeutics to antibiotic-resistant bacteria using an innovative technology platform based on the biology of jumbo phages.

Dr Christopher Longshaw

Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer

Christopher Longshaw studied Medical Microbiology at Leeds University, UK, gaining his PhD for work on the colonisation factors of coagulase-negative staphylococci. He joined Cubist Pharmaceuticals in 2001, working on a joint EU-project to find novel ways to prevent spread of antimicrobial resistance via inhibition of conjugative plasmid transfer. After a period with Syngenta BioPharma screening for novel medicinal antimicrobials from agrochemical libraries, he swapped R&D for Medical Affairs, joining Wyeth Pharmaceuticals UK (later Pfizer UK) as Scientific Advisor for their Anti-infective portfolio which included pipericillin-tazobactam and tigecycline. He joined Astellas Pharmaceuticals Europe in 2010 as Associate Director for Microbiology, working on the development, launch and commercialisation of multiple antimicrobials including telavancin, fidaxomicin, micafungin and isavuconazole and was Country Medical Affairs Manager for Basilea Pharmaceuticals, supporting the commercialisation of isavuconazole and ceftobiprole in the UK.

He joined Shionogi Pharmaceuticals in 2017 as EU Scientific Advisor for Infectious Diseases and works with medical, commercial and development teams at National, European and Global levels to provide medical and scientific leadership, most recently focused on the regulatory approval of the antibiotic, cefiderocol.

He has co-authored numerous peer-reviewed publications including high impact journals such as Lancet Infectious Disease and Eurosurveillance and was one of the EFPIA co-leads within the Innovative Medicines Initiative/New Drugs 4 Bad Bugs project, DRIVE-AB. Chris is a member of the Scientific Committee for Antibiotic Research UK and has been a member of council for the British Society for Antimicrobial Chemotherapy and Industry representative for the Resistance Surveillance Working Group before taking up the office of Honorary Treasurer from 2018.

Dr Alison Luckey

Senior Medical Lead, GARDP

Alison Luckey joined GARDP in September 2021 as Medical Lead for the Zoliflodacin program.

As a Pharmaceutical Physician, she brings a wealth and breadth of experience to the team as a result of her 22-year clinical research career, the last 8 years of which have been within late phase drug development in the anti-infectives therapeutic area. As EFPIA Lead (Astra Zeneca and Pfizer) for Innovative Medicine's Initiative's (IMI) COMBACTE CARE consortium, she has most recently been instrumental in developing and maintaining essential public-private collaborations, leveraging unique opportunities and novel ways of working, to successfully deliver the first interventional Phase 2a study of the program and start-up of a Phase 3 program through two corporate transitions and a pandemic.

Prior to this, she has worked as a Clinical Research Physician and Principal Investigator in early phase development in both the United Kingdom and New Zealand. Together with colleagues, she established a CRO in New Zealand with a 10-bedded facility specialising in early phase development, including First in Man studies and providing an end-to-end service for small biotech companies as well as large pharma. During this time, she was Deputy Chair of the Upper South Regional Ethics Committee, Ministry of Health, New Zealand.

She is a medical graduate (Southampton, UK, 1992) with post graduate clinical experience in Obstetrics & Gynaecology; she holds the Diploma of Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians.

Dr Yukari Manabe

Professor of Medicine, Johns Hopkins School of Medicine, Director, Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases

Yukari Manabe is Director of the Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases and an infectious disease clinician researcher in the Department of Medicine, Division of Infectious Diseases within the Johns Hopkins University School of Medicine. She also holds joint appointments in the Johns Hopkins Bloomberg School of Public Health Departments of International Health and Molecular Microbiology and Immunology and is also the Associate Director of Global Health Research and Innovation within the Johns Hopkins Center for Global Health. Her research has focused on infectious disease diagnostics for STI's, HIV, tuberculosis, and respiratory viruses (COVID-19, influenza) and their impact on patient-centered outcomes. The Center has pioneered STI mail-in self-collection with I Want The Kit, a public health service. She is dedicated to accelerating infectious disease diagnostic development, innovation, and access to increase diagnostic certainty and targeted treatment to improve global health.

Yukari is an author of more than 300 peer-reviewed publications. She obtained her undergraduate degree from Yale University and her MD from Columbia University College of Physicians and Surgeons. She joined the Johns Hopkins School of Medicine faculty in 1999 after completing her residency in internal medicine and fellowship in infectious diseases at Johns Hopkins Hospital. From 2007-2012, she was seconded to the Infectious Diseases Institute where she was the Head of Research and still holds an honorary appointment at Makerere University College of Health Sciences in Uganda.

Gregory Merril

Board Director, BiomX

Gregory Merril was the founding CEO of Adaptive Phage Therapeutics (APT) now BiomX (NYSE: PHGE) where he continues to serve on the Board of Directors. At APT, he pioneered a method for delivering personalized antimicrobial phage therapy at scale and established a first-in-class GMP manufacturing facility. Additionally, Greg successfully implemented an AI/ML team that developed a system to rapidly predict the efficacy of phages in treating AMR infections and formed a collaboration with Mayo Clinic Laboratories with a goal to make personalized phage therapy globally accessible. Prior to APT, he was the founding CEO of HT Medical Systems, focusing on computer-based surgical training simulators (now Immersion Corp, NASDAQ: IMMR). Greg is a prolific inventor with 22 issued patents. Currently, he lends his expertise to various startups, taking on roles from strategic advisor to Executive Director.

Dr Francois Moreau

Chief Scientific Officer, Tamrisa Innovation

François received his PhD in Bioorganic Chemistry at the Sorbonne University Paris, and has 25 years of experience in drug discovery. After 6 years at Pfizer in assay development and biochemistry for allergy / respiratory diseases, François joined Mutabilis in 2004 to explore the possibilities of inhibiting bacterial virulence. He also contributed to the development of a new class of antibacterials, the FabI inhibitors, and a new class of antiretrovirals, the allosteric inhibitors of HIV integrase. His current focus is on the development of the diazabicyclooctanes as a novel class of antibacterials targeting the Penicillin-binding proteins and showing outstanding stability to class A, B, C and D beta-lactamases. François is co-author of 24 articles and co-inventor of 11 patents.

Dr Maneesh Paul

CEO, Microvioma

Maneesh Paul-Satyaseela is the lead co-inventor of Enmetazobactam – the first invented-in-India anti-infective to be approved by USFDA. Since 2006, as its Program Director at Orchid Pharma, Chennai he led the invention as a biologist (along with medicinal chemist Senthilkumar UP), and is continuing to drive its approval and Phase-4 studies in India (Allecra Therapeutics GmbH, after in-licensing it, conducted its clinical trials and Regulatory approval at EMA, UKMHRA, & USFDA). He is one of the first Indian non-clinician to be conferred with the Fellow of Infectious Diseases Society of America (FIDSA).

He is trained at MAHE & Kalaburagi Univ. (India), CBER-USFDA (ORISE Fellow), Johns Hopkins Medical Institutions (Peds ID), USA & at Umea Univ. Sweden (ID), and has nearly 40 publications and 5 co-inventions (patents) to his credit. He serves as a member of UKRI's Strategic Advisory Committee on PACE (2024-2029), Revive of GARDP (since 2019, https://revive.gardp.org/maneesh-paul) and three Biotech & skills Steering committees of Govt. Karnataka (India, 2024-25); was on IDSA's Research (2017-19, 2023-24), and AMR Committees (2019-22). In Bengaluru (India), he has led trans-disciplinary research at Acharya Institutions, post-graduate medical research in 7 clinical disciplines at St. Martha's Hospital, and was a clinical microbiologist at KIMS.

An AMR steward, techno-commercial enabler, influencer, & an innovator with broad research expertise in mechanisms of infectious diseases, he currently provides Advisory solutions to several organizations in microbiology & anti-infectives, and promotes planetary health & antimicrobial stewardship through AMRACE (AMR Action Collaborative Engagement, www.maneeshpaul.com)

Dr Liise-anne Pirofski

Physician-scientist & Chief, Division of infectious diseases & Dr Jacques and Selma Mitrani Chair, Biomedical Research, Albert Einstein College of Medicine & Montefiore Medical Center

Liise-anne Pirofski is a physician-scientist and chief of the division of infectious diseases and the Dr. Jacques and Selma Mitrani Chair in Biomedical Research at Albert Einstein College of Medicine and Montefiore Medical Center. Her research programs are focused on antibody immunity to infectious diseases. She is a member of the American Association of Physicians (AAP) and a fellow of the American Academy of Microbiology (AAM), Infectious Diseases Society of America (IDSA), and the American Association for the Advancement of Science (AAAS). She is deeply devoted to biomedical education and mentoring, for which she has received numerous accolades, including the ASM William A Hinton Award for Advancement of a Diverse Community of Microbiologists, the Albert Einstein College of Medicine Faculty Mentoring and Harry Eagle Award for Outstanding Basic Science Teaching, the Lifetime Achievement Award from the Albert Einstein College of Medicine Alumni Association, and the IDSA Walter E. Stamm Mentor Award.

Dr Teri Roberts

Public Health Senior Manager, GARDP

Teri joined GARDP in 2023 as a Public Health Senior Manager. Teri is a biomedical scientist specialised in infectious diseases and issues concerning resource-limited settings, and has worked on global health issues for more than 2 decades in Switzerland and South Africa. While technically specialised, Teri also works on policy and access issues and routinely works with the WHO and other global health actors and advocacy groups. Teri has previously held senior positions at EGPAF, the International AIDS Society, the MSF Access Campaign, and FIND, the global alliance for diagnostics, as well as working as a freelance consultant. Teri has a PhD in Biomedical Sciences from Stellenbosch University, specialising in immunology and tuberculosis, and had two post-doctoral positions and a research role at the Desmond Tutu HIV Centre, before moving from Cape Town to Geneva.

Halley Rogers

Director, Clinical Research, Clinical Development and Operations, Pfizer, Inc.

Halley Rogers is a Director of Clinical Research and Lead Study Clinician at Pfizer, Inc, focusing on interventional clinical trials in anti-infectives. She has worked across multiple trial stages, study sizes and therapeutic areas during her time in the clinical research industry. She brings a unique perspective as a result of working in various academic medical centers in the US, before moving into the pharmaceutical sector. Halley served as the President of the Association for Clinical Research Professionals for the NY Metropolitan Chapter, and within Pfizer is involved in multiple workstreams at Pfizer to improve the patient experience in research.

Posters

DISCOVERY & EXPLORATORY RESEARCH

Investigating the Antibacterial Activity of Medicinal Plant Infusions against Pathogenic Bacteria

Tesleem Ibrahim

Queen's University Belfast, United Kingdom

- - - - - -

Evaluation of the physicotechnical and antimicrobial bioload of two locally produced herbal dry gins in Nigeria

John Dike Nwabueze Ogbonna

University of Nigeria, Nsukka, Nigeria

- - - - - -

Isolation and Characterization of Bacteriophages as Potential Therapeutics Against Mycobacterial Infections

Sandra Benin

Research Assistant, West African Center for Cell Biology of Infectious Pathogens, Ghana

- - - - - -

Exploring the resistome, virulome, and mobilome of carbapenem multidrug-resistant Klebsiella pneumoniae isolates

Saadia Andleeb

Professor at NUST, Pakistan

- - - - - -

Determination of multidrug resistance in aquaculture

Frances Nathan-Mensah

Council for Scientific and Industrial Research-Animal Research Institute, Accra, Ghana

- - - - - -

Molecular characterization of Acinetobacter baumannii in Iraq

Soza Tharwat Baban

Infection prevention and control specialist, Surgical Specialty Hospital, Cardiac Center, Iraq

- - - - - -

Prevalence and Drug-Resistance Phenotype Of Salmonella spp., Shigella Spp., And Escherichia Coli Associated to Water Physicochemical Properties in the Nyong Watershed, Centre Region of Cameroon

Johngwe Mac Juliette Njekeh

Intern at the Cameroon Epidemio-surveillance Network for Animal Diseases (CENAD), Cameroon

- - - - - -

Computational study to identify novel Metallo-β-lactamases inhibitors using virtual screening, molecular docking, dynamic simulations, and ADMET prediction

Fatima Mourabiti

University of Casablanca, 20100. Casablanca, Morocco

- - - - - -

Antibacterial Activity of Aqueous Extracts Of Some Selected Spices On Esbl Escherichia Coli Isolated from an Abattoir Effluent

Martha Ajuga

Department Of Biology/Microbiology, Abia State Polytechnic, Aba, Abia State, Nigeria

- - - - - -

Reversion of heme-dependent metronidazole resistance in Clostridioides difficile

Abiola Olaitan

Assistant Professor/University of Waterloo, Canada

- - - - - -

Lawsonia inermis (Henna) Extracts as a Sustainable Solution to Combat Multidrug-Resistant Gram-Negative Bacteria in Surface Water, Sewage, and Abattoir Leachate: A Quantitative Antimicrobial Analysis

Morufat Olaitan

Lecturer and Researcher, Nile University of Nigeria, Abuja, Nigeria

- - - - - -

Low-Generation Cationic Phosphorus Dendrimers: Novel Approach to Tackle Drug-Resistant S. aureus In vitro and In vivo

Abdul Akhir

Research Scholar at CSIR-Central Drug Research Institute Lucknow, India

- - - - - -

Understanding the role of Multifaceted Defense Mechanisms of Acinetobacter spp.

Saadlee Shehreen

Lecturer, Teesside University, UK

- - - - - -

HSD 1624 as an adjuvant of colistin for Multidrug resistant bacteria

Martha Asare

Graduate student / West African Center for Cell Biology and infectious Pathogens- University of Ghana, Ghana

- - - - - -

Synergistic Antimicrobial peptides and Antibiotics: A Novel Approach for Biofilm-Associated Infection Management

Afifa Shafqat

College of Pharmacy, University Of Punjab, Lahore, Pakistan

- - - - - -

Antibiotic Resistance Profiling of Gram-negative Bacteria from Pharmaceutical Effluents of Industrial Areas of Himachal Pradesh

Yukta Arora

PhD Researcher, Eternal University, India

- - - - - -

Antifungal Therapy and Pesticides: Is There a Connection?

Anastasiia Hrynzovska

postgraduate of the Department of microbiology and parasitology with the basics of immunology Bogomolets National Medical Universit, Ukraine

- - - - - -

Revealing the Power of Bioactive Substances in Combating Microbial and Oxidative Stress

Hajar Boughroud

Pasteur Institute of Morocco- Hassan II university, Faculty of Sciences Ain Chock, Morocco

- - - - - -

Utilising actinobacteria diversity in the Great Salt Plains to look for novel TB therapeutics

Amanda Jones

Associate Professor in Microbiology at Northumbria University, UK

- - - - - -

Antibiotic susceptibility pattern of heavy metal tolerant, Gram-negative bacteria isolated from Lapite dumpsite, Ibadan, Nigeria

Blessing Nwadike

Doctor of Philosophy, University of Ibadan, Nigeria

- - - - - -

Extending the Potency and Lifespan of Antibiotics: Inhibitors of Gram-Negative Bacterial Efflux Pumps

Maëlle Duffey

GARDP, Switzerland

- - - - - -

Unveiling Resistance Pathways in Arcobacter butzleri: Evolutionary Insights by Low Ciprofloxacin Concentrations Exposure

Inês Martins

hD Student at CICS-UBI – Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal

- - - - - -

In Vitro Antibacterial Effects and In Silico Toxicity Analysis of Thymus mastichina and Eucalyptus cinerea Essential Oils

Siham Fathallah

PhD Student at Hassan II University, Morocco

- - - - - -

Molecular and functional characterization of Clostridioides difficle cyclic di-AMP binding GntR in response to physiological stresses and Antimicrobial Resistance

Chankit Giri

Ph.D scholar at CSIR-Institute of Microbial technology, India

- - - - - -

Innovative Strategies Against AMR: Advancing NCL-195 Development through Self-Emulsifying Formulation and In Silico Drug Design

Songhita Mukhopadhyay

University of South Australia, Australia

- - - - - -

Antibiotic Resistome characterization of Genetically Unrelated Biocide Tolerant Extremely Drug Resistant Acinetobacter baumannii

Karthikeyan Krishnan

Ph.D scholar at CSIR-Institute of Microbial technology, India

- - - - - -

Effect of Iron Homeostasis on Antimicrobial Resistance in Escherichia Coli

Naveenraj Rajasekar

Ph.D scholar at CSIR-Institute of Microbial technology, India

- - - - - -

Enzymatic Solutions for Antibiotic Deactivation to Address Antimicrobial Resistance

Marik Müller

Undergraduate Researcher, University Heidelberg, Germany

- - - - - -

Triclosan synergistically potentiates polymyxin B activity in colistin resistant Klebsiella pneumoniae

Pushney Mahapatra

Research Intern, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) Deemed to be University, India

- - - - - -

Identification of host microRNAs regulating the infection of macrophages by invasive and non-invasive Salmonella strains

Susana Costa

PhD candidate - Center for Neuroscience and Cell Biology, University of Coimbra, Portugal

- - - - - -

Unveiling the antibacterial efficacy of a Benzonitrile small molecule, IITR00210 in Shigella infection

Jawed Akhter Akhter

Research Scientist at Venus Medicine Research Centre, Venus Remedies Ltd, Himachal Pradesh India

- - - - - -

Functional high-throughput screening identifies microRNAs regulating infection by Staphylococcus aureus

Caio Franco

Postdoctoral Researcher - AccelBio Collaborative Laboratory/ University of Coimbra, Portugal

- - - - - -

Antagonistic Activity Exhibited by Marine Isolate, Bacillus cabrialesii against Antibiotic-Resistant Clinical Pathogens

Ishita Raninga

Research Scholar, Department of Microbiology, Atmiya University, Gujarat, India

- - - - - -

Antimicrobial evaluation of extract from endophytic fungus Hypomontagnella barbarensis and isolation of tetronic acid derivatives using metabolomic approach

Lhais Caldas

PhD - Universidade Federal de Sao Paulo, Brazil

- - - - - -

On the Search for Novel Antibiotics Targeting the Methylerythritol Phosphate Pathway in Gram-Negative Bacteria

Frederik Gerteis

PhD Student, Fraunhofer ITMP, Germany

- - - - - -

High-throughput Screening identifies bioactive compounds targeting intracellular Staphylococcus aureus

Laura Alcântara

Postdoctoral Fellow, University of Coimbra, Portugal

- - - - - -

Integrative SAR and kinetic studies lead to the identification of a broad-spectrum serine-β-lactamase inhibitor for combating carbapenem resistance

Perwez Bakht

Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand, India

- - - - - -

Discovery & Exploratory Research at the Global Antibiotic Research & Development Partnership (GARDP): Objectives and Progress

Benjamin Blasco

Senior Discovery Project Manager, GARDP

- - - - - -

Plantimicrobials: Unlocking the antimicrobial potential of botanical epiphytic bacteria

Darshana Srivastava

PhD student, University of Plymouth, UK

- - - - - -

Deciphering host-Rickettsia interactions: moonlighting APRc recruits human complement regulator C4BP acting as an evasin

Ana Luísa Matos

PhD student, CNC - Center for Neuroscience and Cell Biology, Portugal

- - - - - -

In vitro synergistic activity of the sulbactam/avibactam combination against carbapenem-resistant Acinetobacter baumannii from Peruvian hospitals

Rosario del Pilar Huerto Huánuco

Junior researcher at Southern Scientific University, Peru

- - - - - -

Manganese Dependent SodB mediates the Pathophysiological Fitness of Acinetobacter baumannii 5075 under Oxidative Stress

Ashish Kumar Ray

PhD Scholar, Indian Institute of Technology Roorkee, India

- - - - - -

EpiLeish: the impact of m6A RNA modification in Leishmania drug resistance

Artur Reis

Departamento de Microbiologia, Imunologia e Parasitologia – Escola Paulista de Medicina – Universidade Federal de São Paulo, Brazil

- - - - - -

Leveraging Digital Healthcare to Address Antimicrobial Resistance in Kyrgyzstan: Insights from Discovery and Exploratory Research

Mohd Faizan Siddiqui

International Medical Faculty, Osh State University, Osh City, Kyrgyzstan

- - - - - -

Predictive Analytics in Tuberculosis Drug Research: Cell Wall Inhibitor

Afreen Khan

SVKM's Dr. Bhanuben Nanavati College of Pharmacy, India

- - - - - -

Exploiting UniProt enzyme annotation to identify new antibacterial drug targets

Christopher Southan

Honorary Professor, University of Edinburgh, UK

- - - - - -

Pyrvinium pamoate potentiates levofloxacin against levofloxacin-resistant Staphylococcus aureus

Deepanshi Saxena

Researcher at CSIR-Central Drug Research Institute, Lucknow, U.P., India

- - - - - -

Investigation on various parameters influencing virulence of bacterial pathogens towards the model host Caenorhabditis elegans, and major mode of worm killing by different pathogens

Vijay Kothari

Senior Faculty, Institute of Science, Nirma University, India

- - - - - -

Repurposing approved drugs to target efflux pumps

Tania Szal

Fraunhofer ITMP, Germany

- - - - - -

Investigation of the Antiulcer and Antimicrobial Effects of Chromolaena odorata Leaf Fractions

Akachukwu Onwuka

Lecturer/ 1Department of Pharmacology & Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nigeria

PRE-CLINICAL RESEARCH & DEVELOPMENT

Prevalence and associated risk factors of Vancomycin resistant Enterococcus faecium in well water used for domestic purposes in Ile-Ife, South western Nigeria

Babatunde Odetoyin

Lecturer, Obafemi Awolowo University, Ile-Ife, Nigeria

- - - - - -

A Multicenter Global Point-Prevalence Survey of Antimicrobial prescription and healthcareassociated infections in Iraq: The need for Urgent Action

Soza Baban

Infection prevention and control specialist, Surgical Specialty Hospital, Cardiac Center, Iraq

- - - - - -

Occurrence and Diversity Of Tetracycline Resistance Genes in Enterobacteriaceae from Wound Samples in Port Harcourt, Nigeria

Seleipiri Horsfall

Lecturer, University of Port Harcourt, Nigeria

- - - - - -

Building an on-panel enzyme detection system to reveal and resolve clinically problematic beta-lactamases in Gram negative bacteria

Nicole Jackson

BioAmp Diagnostics, US

- - - - - -

Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria

Sohinee Sarkar

Senior Research Fellow, Murdoch Children's Research Institute, Australia

- - - - - -

Parallel development of Corallopyronin A for global health: oral treatment of filarial nematode infections and Staphylococcus spp. biofilm infections

Kenneth Pfarr

Senior Scientist, Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany

- - - - - -

Analysis of Antimicrobial Drug Sensitivity in Kyrgyzstan: A Comparative Study Before and After the COVID-19 Pandemic

Abdimomunova Begimai Toktobolotovna

Senior lecturer of the Department of Public health, International Medical Faculty, Osh State University, Kyrgyzstan

- - - - - -

In vitro infection model studies to understand the novel antibiotic class from a Pharmacokinetic/Pharmacodynamic perspective

Kashaf Khalid

Helmholtz Center for Infection research, Germany

- - - - - -

A Novel Approach to Universal Nephroprotection in Polymyxin (Colistin)-Based MDR Treatments

Boris Farbe Farber

TRIZ Biopharma Innovations LLC, US

EARLY CLINICAL DEVELOPMENT (PHASE 1, 2)

INCAS: a Phase2 trial investigating interferon gamma as an adjunctive therapy for chronic pulmonary aspergillosis

Beth Bradshaw

Medical Writer, National Aspergillosis Centre (Manchester University NHS Foundation Trust), UK

OTHER

Molecular and phenotypic characterization of biofilm formation and antimicrobial resistance patterns of Staphylococcus aureus isolated from patients with urinary tract infections in Casablanca, Morocco

Rafik Anibaa

Casablanca

- - - - - -

A Prospective Study on Prevalence of Blood culture Isolates and it's antibiogram in a tertiary care hospital in South India

Sriram Radhakrishnan

Pharm D Intern, C.L. Baid Metha College of Pharmacy Affiliated to the Tamil Nadu Dr. M.G.R Medical University, India

- - - - - -

The Assessment of CRISPR-Cas and Antibiotic Resistance Genes in the Selected Enterococcal Strains for Their Probiotic Validation

Abrar Hussain

University of Karachi, India

- - - - - -

Investigation of the potential of Curcuma longa and Allium sativum to induce antimicrobial resistance at sublethal concentration against clinical pathogens

Amin Amin

University of Rajshahi, Rajshahi-6205, Bangladesh

- - - - - -

Carbapenem-Resistant Acinetobacter baumannii: The Serial Killer Still at Large

Manel Ennaceur

Habib Thameur Hospital, Tunis, Tunisia

- - - - - -

Bacteriological analysis of Effluents from Selected Restaurants within Joseph Ayo Babalola University

Olalekan Balogun

Lecturer and Joseph Ayo Babalola University, Nigeria

- - - - - -

Audit of Enhancing Antimicrobial Stewardship: A Prospective Evaluation of Intervention Strategies

Hythum Mohamed

Doctor, Geraldton Regional Hospital, Australia

- - - - - -

Investigating the Efficacy of Novel Antimicrobial Chemotherapy Strategies Against Multidrug-Resistant Pathogens

Munaza Rasheed

Department of Microbiology, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan

- - - - - -

Novel Antimicrobial Chemotherapy Strategies: A Multifaceted Approach to Combat Resistant Infections

Saad Ahmed Khan

Cholistan University of Veterinary and Animal Sciences Bahawalpur, Pakistan

- - - - - -

The value of using FilmArray-type multiplex PCR in the diagnosis of central nervous system infections

Farouk Barguellil

Military Hospital of Tunis and LR19DN03 (Micro-organisms and the environment: molecular diagnostic tools and emerging and re-emerging infections), Tunisia

- - - - - -

Gender-specific antibiotic-resistance patterns and characterization of bacterial flora of undergraduate students' mobile phones and associated factors at a Nigerian University

Morufat Olaitan

Lecturer and Researcher, Nile University of Nigeria, Abuja, Nigeria

- - - - - -

Surveillance of Vancomycin-Resistant Enterococci by Determination of the Van A Gene by PCR

Farouk Barguellil

Military Hospital of Tunis and LR19DN03 (Micro-organisms and the environment: molecular diagnostic tools and emerging and re-emerging infections), Tunisia

- - - - - -

Outbreak of multi drug resistant Serratia marcescens in a tertiary Pediatric Care Unit in Pakistan: Epidemiological Insights and Infection Control Strategies

Yusra Shafquat

Consultant Microbiologist, Liaquat University Of Medical and Health Sciences, Pakistan

- - - - - -

Impact of Biannual Mass Drug Administration of Azithromycin on Child Mortality: A Systematic Review and Meta-Analysis

Madhusudan Prasad Singh

DM Clinical Pharmacology Resident, Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India

- - - - - -

Evaluating the Necessity of Antibiotic Prophylaxis to Prevent Surgical Site Infections in Clean Surgeries: A Systematic Review

Laurentia Fidella Averina Setia Santoso

Clinical Clerkship at Faculty of Medicine, Universitas Padjadjaran, Sumedang, Indonesia

- - - - - -

An innovative concept to address chemical in-use stability of antibiotics

Eva Littringer

Chief scientific officer, RevIVe Medtech GmbH, Kufstein, Austria

- - - - - -

Impact Evaluation of Guidelines on Antibiotic Utilisation & Appropriateness in Malaysian Public Primary Care: an Interrupted Time Series Analysis

Audrey Huili Lim

Pharmacist, Institute for Clinical Research, Malaysia

- - - - - -

Bloodstream infections (BSIs) in Internal Medicine Department (IMD) – eetiology and antibiotic therapy in 3-year observation study

Piotr Piekiełko

M.D., Center of Pulmonology and Thoracic Surgery in Bystra, Poland

- - - - - -

The threat of carbapenem resistant bacteria in adult ICU in a tertiary care hospital in Tabuk, Saudi Arabia: a retrospective observational single centre study

Rehab Ahmed

Assistan Professor, Faculty of Pharmacy, University of Tabuk, Saudi Arabia

- - - - - -

Carriage of methicillin-resistant Staphylococcus aureus among healthcare workers in Libyan hospitals

Ahmed Khalaf

Principal Investigator. Ministry of health, Tripoli, Libya

- - - - - -

Antibiotic use in pediatric outpatients in Georgia; prevalence, proportion, and compliance with guidelines

Irma Korinteli

Tbilisi State Medical University, Georgia

- - - - - -

AntibioticDB 2.0: an improved open-access database of antibacterial agents to support research and development of new treatments

Luiza Galarion

University of Leeds, UK

- - - - - -

1990 - 2021 Trend in fatal burden from infections resistant to antibiotics across the UK

Gisela Robles Aguilar
GBD 2021 Antimicrobial Resistance Collaborators, University of Oxford, UK

- - - - - -

High incidence of Helicobacter pylori resistance to metronidazole in Moroccan pediatric patients

Fatima Zahra Kheir
PhD student / faculty of science El Jadida, Morocco

- - - - - -

Evaluation of antibiotic prescription in primary care medicine

Meriam Abdeljelil
Infectious Diseases Department, Monastir University Hospital, Tunisia

- - - - - -

Strategies for Periprosthetic Joint Infection Management in Resource-limited Settings: The Applicability of EBJIS Criteria

Meriam Abdeljelil
Infectious Diseases Department, Monastir University Hospital, Tunisia

- - - - - -

Accuracy of Antimicrobial Susceptibility Test Reporting for Proteus mirabilis: A Nationwide Surveillance

Yunika Puspa Dewi
Dr. Sardjito General Hospital, Indonesia

- - - - - -

Assessing the antibiotic resistance in high larvicidal Bacillus thuringiensis var. israelensis strains used for mosquito control

Sankari Thirumal
Senior Technical Officer, Indian Council of Medical Research - Vector Control Research Centre, India

- - - - - -

Mitigating AMR in small-scale farms of Peru at the One Health interface

Marília Salgado Caxito
Postdoctoral Researcher – Institut de Recherche pour le Développement (IRD), France

- - - - - -

Moulds Isolated from patients in 22 ICUs: Focus on Aspergillus fumigatus and its Antifungal Susceptibility Profile

Laura Alguacil Cuéllar
PhD Candidate - Instituto de Salud Carlos III, Spain

- - - - - -

Nasal and recto-vaginal colonization of MRSA in term pregnant women, Eastern province, Sri Lanka

Fathima Siromiya Shamil Mafras
Lecturer, University of Jaffna, Sri Lanka

- - - - - -

Isolation and Characterisation of Sulfonamide Resistant bacteria obtained from Animal waste

Oluwafunmilayo Olajide
Lecturer, Gateway (ICT) Polytechnic Saapade, Nigeria

- - - - - -

Real-World Impact of Digital NEWS2 Alert on Antimicrobial Use in Clinical Deterioration: A Defined Daily Dose Analysis

Chen Chuan Kuai
Pharmacist, University College London Hospitals NHS Foundation Trust, United Kingdom

- - - - - -

Pipeline of Novel Therapies and Investment for Carbapenem Resistant Acinetobacter Baumannii: a WHO critical priority pathogen

Karla Ordoñez
Student, Newcastle University, United Kingdom

- - - - - -

Emergence of Multidrug-Resistant Klebsiella pneumoniae in Tunisian University Hospital (2022)

Zied Fehri
Biologist Physician / Microbiology Laboratory, Sahloul University Hospital, Sousse, Tunisia

- - - - - -

Emergence of Imipenem-Resistant A. baumannii Strains: A Cross-Sectional Study in a Tunisian University Hospital (2022)

Zied Fehri
Biologist Physician / Microbiology Laboratory, Sahloul University Hospital, Sousse, Tunisia

- - - - - -

Neonatal Sepsis"- Gram Positive & Negative Bacteria's and their Antibiotic Susceptibility in NICU

Jibi Thankachan
King Saud Medical City, Saudi Arabia

- - - - - -

On the Front Lines of Infection Control: How Antimicrobial Ward Rounds Drive Stewardship Success

Miguel Vella
Wexham Park Hospital, UK

- - - - - -

Comparison of Different Methods for Evaluating Colistin Susceptibility: Is There a Reliable Correlation?

Manel Ennaceur

Habib Thameur Hospital, Tunis, Tunisia

- - - - - -

Multilocus Sequence Typing of Hospital-Associated Vancomycin – Resistant Enterococcus from Malaysia Reveals high Clonal Lineage of CC17 clonal complex

Yusuf Wada

Lecturer, Ahmadu Bello University Zaria, Nigeria

- - - - - -

Point-of-care monitoring of resistance genes with Bactometer for optimal antimicrobial therapy and stewardship strategy

Maria Leonor Santos

PhD student, EnviHealthMicro Lab, Institute of Environmental Health (ISAMB), Associate Laboratory TERRA, Faculdade de Medicina, Universidade de Lisboa - Lisbon, Portugal

- - - - - -

Assessment of Occurrence Of Multidrug Resistant Escherichia Coli from a Major Abattoir in Aba, Abia State, Nigeria

Martha Ajuga

Department of Biology/Microbiology, Abia State Polytechnic, Aba, Abia State, Nigeria

- - - - - -

An exploration into the Functioning of Ecosystems Combating Antimicrobial Resistance

Daniel Marshall

Postgraduate Researcher at Anglia Ruskin University, UK

- - - - - -

Pharmacist-Led Antibiotic Interventions in Infectious Disease Patients: A Pakistani Tertiary Care Antimicrobial Stewardship Study

Ali Hassan

Student at Faculty of Pharmacy, Gomal University, Pakistan

- - - - - -

Ongoing Exploration of Antibiotic Use in Patients with Influenza Rapid Antigen Testing

You-Yu Liao

Medical technologist, Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

- - - - - -

Assessment of the coherence of antibiotics used in urinary tract antibiograms in accordance to the latest guidelines of the European Association of Urology 2023

Cezary Kapturkiewicz

Student at Students' Scientific Group of Microbiology, Chair of Microbiology, Jagiellonian University - Medical College, Poland

- - - - - -

Intravenous to Oral Switch in complex infections. A cross- sectional study of antimicrobial treatment in the Belfast Health and Social Care Trust (BHSCT)

Leeanne Stewart

Belfast Health and Social Care Trust, UK

- - - - - -

Assessment of multidrug resistance in Pseudomonas sp. isolated from wounds at the University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria

Kemuel Nyema

Graduate assistant, University of Port Harcourt, Nigeria

ACCESS

Acinetobacter Species as Uropathogen and its Antibiogram at a Tertiary Care Hospital

Shobha K.L

Microbiologist and teacher, Department of Basic Medical Sciences, Manipal Academy of Higher Education, Manipal, India

- - - - - -

Antibiotics susceptibility of Klebsiella pneumoniae among adult and children

Yi-Ting Chen

Medical Technologist /Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

- - - - - -

Towards a new communication strategy to increase access of novel antibiotics

Samkele Mkumbuzi

University of Cape Town, South Africa